87 results about "Liver lipid" patented technology

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a duochin in preparation of a medicine for treating MASLD. The research finds that the eriochin has a positive effect on treatment of MASLD, and can effectively delay the body weight, liver weight and liver weight-body weight ratio of MASLD mice, relieve liver injury, relieve liver lipid deposition, liver fatty degeneration, inflammation and fibrosis and delay the MASLD disease progress. Research finds that the eriochin can effectively reduce body weight, relieve liver injury and relieve fatty degeneration and inflammation of the liver, so that MASLD is improved. The invention provides a new thought for the treatment research of MASLD.

The invention discloses application of a substance taking MANF as a target spot in preparation of a medicine for treating non-alcoholic steatohepatitis. The research finds that the expression of the MANF in liver tissues of a fatty liver patient and a non-alcoholic steatohepatitis model mouse is obviously up-regulated, and the weight, liver lipid accumulation and inflammatory infiltration of the NASH mouse can be obviously reduced by specifically knocking out the MANF by the macrophage, so that the MANF in the macrophage plays an important role in the NASH pathological process.

The invention discloses liquiritigenin and isoliquiritigenin produced by directionally converting liquiritin and isoliquiritigenin through lactobacillus plantarum CCFM1275 and application of the liquiritigenin and the isoliquiritigenin. Researches show that the lactobacillus plantarum CCFM1275 can grow in a fermentation base material rich in a licorice extract, and liquiritin and isoliquiritin in licorice can be converted into liquiritigenin and isoliquiritigenin respectively, so that utilization of active ingredients of liquiritin and isoliquiritigenin by an organism is facilitated, and the effect of the licorice extract is improved. Compared with the licorice root extract, the fermented licorice root postbiotics obtained by fermenting and converting the licorice root extract through the lactobacillus plantarum CCFM1275 can further improve the effects of the licorice root extract in the aspects of reducing liver lipid accumulation, lowering lipid and resisting aging, can be used for preparing products with the effects of preventing and / or treating fatty liver and obesity and / or resisting aging, and has a huge application prospect.

The invention provides a preparation method of an apple water kefir beverage and application of the apple water kefir beverage in lowering cholesterol. The method comprises the following steps: preparing apple juice, activating water kefir grains, inoculating the activated water kefir grains into the apple juice, and fermenting to prepare the apple water kefir beverage. The volatile component change in the fermentation process is analyzed through GC-MS and GC-IMS systems, it is proved that the unique bouquet characteristic and flavor coordination of the apple water kefir beverage are improved through water kefir grain fermentation, and meanwhile the organic acid composition is optimized. A mouse model verifies that the apple water kefir beverage has the effect of reducing cholesterol, can reduce liver lipid droplets, total cholesterol, low-density lipoprotein and triglyceride levels, and also can regulate intestinal microbial communities (increase firmicobacteria, bacteroides and faecalis bacteria). The apple water kefir beverage disclosed by the invention has wide market potential and provides a scientific basis for the development of functional beverages.

The invention provides a non-alcoholic fatty liver disease zebra fish model and a construction method thereof, and relates to the technical field of genetic engineering and molecular biology. The sgRNA of the targeted zebrafish fads2 gene contains a guide sequence which can be specifically combined with a nucleotide sequence shown as SEQ ID NO.4 in the fads2 gene. The sgRNA targeting the fads2 gene of the zebrafish can accurately and efficiently target and knock out the fads2 gene of the zebrafish, so that a non-alcoholic fatty liver model which is caused by DHA (docosahexaenoic acid) deficiency and is represented by liver lipid accumulation is successfully constructed, and the sgRNA is a key technical tool for constructing a specific disease model.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The present application relates to a new use of Fuling Gancao Decoction, and specifically discloses application of Fuling Gancao Decoction in treatment of hyperlipidemia, wherein the Fuling Gancao Decoction is composed of the following components in parts by weight: Fuling 2 parts, Guizhi 2 parts, Zhigancao 1 part and Shengjiang 3 parts. It is found through animal experiment research that the Fuling Gancao Decoction can improve the symptoms of hyperlipidemia rats, reduce the content of TG, TC and LDL-C in serum, improve the liver lipid, blood sugar of hyperlipidemia model animals, reduce the liver coefficient, improve the liver cell fatty degeneration, reverse the pathological morphology of adipose tissue cells and the mitochondrial damage of hyperlipidemia model animals. A new indication of the Fuling Gancao Decoction is found, the development of traditional Chinese medicines is promoted, and a new drug composition with less side effects is provided for treatment of hyperlipidemia.

The application provides a curcumin composition-FGF21 functional protein co-assembly microparticle applied to liver diseases and a preparation method thereof, and comprises the following steps: extracting turmeric by dynamic warm soaking, obtaining turmeric filtrate after centrifugation, concentration and microfiltration; preparing high-purity curcumin composition through PS-NVP specific purification and 80% ethanol gradient elution; and preparing Curs-FGF21 co-assembly microparticles through oil-water phase assembly and centrifugation by taking a polymer as a carrier, compounding the curcumin composition with FGF21 protein. The microparticle can improve drug stability and bioavailability, realizes long-acting slow release, can regulate liver cell lipid metabolism, reduce liver lipid accumulation and inflammation, significantly improves liver damage and liver fibrosis, and has outstanding liver protection and repair effects. The process is stable and controllable, has outstanding innovation, and provides a brand-new candidate preparation research and development idea and technical scheme for the prevention and treatment of metabolic liver diseases.

The invention provides application of an SLC13A3 gene serving as a target spot in preparation of a medicine for treating metabolism-related fatty liver diseases. By constructing an MASLD cell model and an MASLD mouse model with the lesion degree from light to heavy, the expression of the SLC13A3 in the liver tissue and cell model of the metabolism-related fatty liver disease mouse is up-regulated, and the up-regulation multiple is gradually increased along with the increase of the severity of the disease. Animal experiments show that the liver specific knock-down SLC13A3 can significantly relieve weight and liver weight increase, liver fatty degeneration, liver lipid accumulation and liver function impairment accompanied by MASLD, and reduce the expression of adipogenesis genes. The invention provides a new target and a new thought for the development of drugs for treating metabolism-related fatty liver diseases.

The invention relates to Escherichia coli ML001, a specific bacteriophage thereof and an application of the Escherichia coli ML001 in preventing alcoholic liver diseases. The Escherichia coli strain ML001 and the specific bacteriophage thereof are preserved in China General Microbiological Culture Collection Center (CGMCC). Animal experiments prove that the bacteriophage can effectively reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the plasma of an alcoholic liver disease model mouse, which indicates that the bacteriophage has a definite liver protection function. The histopathologic examination further shows that after the phage is administered, the number of lipid droplets in the liver of the mouse is obviously reduced, and the liver lipid accumulation is effectively relieved. On the molecular mechanism level, the bacteriophage can down-regulate expression of fatty acid synthesis genes Srebf1 and Acly at the same time and inhibit a lipid synthesis pathway; meanwhile, the expression of a chemotactic factor Ccl6 is reduced, and the inflammatory response of the liver is relieved.

The invention relates to application of kaempferol in preparation of drugs, food or health care products for preventing or treating liver cancer related to non-alcoholic fatty liver or non-alcoholic fatty liver. According to the kaempferol disclosed by the invention, the liver weight, the liver weight ratio, the tumor quantity and the maximum diameter of the tumor of a mouse with the non-alcoholic fatty liver-related liver cancer are obviously reduced; in histology, the kaempferol can obviously improve hepatic tissue fatty degeneration and liver lipid droplet density, and improve liver cell inflammation and fibrosis degree; kaempferol can obviously reduce the content of cholesterol serum and cholesterol in the liver of a mouse with non-alcoholic fatty liver-related liver cancer, and can reduce liver injury indexes ALT and AST; the kaempferol can obviously reduce the expression level of mRNA related to liver fibrosis of mice with liver cancer related to non-alcoholic fatty liver.

The invention belongs to the technical field of functional microorganism application, and particularly relates to a novel lipid-lowering peptide derived from a probiotic thallus and application thereof, the novel lipid-lowering peptide is a crushed substance derived from a probiotic lactobacillus plantarum thallus, and the molecular weight of the novel lipid-lowering peptide is less than 3kDa. And two key polypeptides APGFGDR (AP7) and TESGAFGR (TE8) are identified from the components, and can specifically inhibit the activities of pancreatic lipase and pancreatic cholesterol esterase. The extracted thallus peptide can be efficiently combined with cholate to inhibit the formation of cholesterol micelles, and has a remarkable inhibiting effect on pancreatic lipase and pancreatic cholesterol esterase. Animal experiments show that the mycopeptide can effectively improve lipid metabolism disorder induced by high fat diet, inhibit weight gain, reduce serum and liver lipid levels and relieve fatty degeneration and inflammation of the liver. The lipid-lowering peptide disclosed by the invention is high in safety and multi-target in action, and can be used for preparing functional products for preventing or treating metabolic diseases such as obesity, hyperlipidemia and the like.

The invention relates to an anti-inflammatory and lipid-lowering-based nano preparation for treating fatty liver and a preparation method of the nano preparation. Galactose modified polyethylene glycol-polylactic acid-glycolic acid copolymer (PEG-PLGA) is used as a targeting carrier, and a lipid-lowering drug fenofibrate and an anti-inflammatory drug curcumin are co-loaded; the particle size of the nano preparation is 150-200nm, and the drug encapsulation efficiency is greater than or equal to 85%. Galactose modified PEG-PLGA is adopted as a carrier, galactose can be specifically combined with an asialoglycoprotein receptor (ASGPR) specifically expressed on the surface of liver cells, active targeting of the liver is achieved, the drug enrichment amount of the liver lesion position is remarkably increased, meanwhile, accumulation of drugs in extrahepatic tissue is reduced, extrahepatic toxicity is effectively reduced, and the drug delivery effect is improved. According to the present invention, the anti-inflammatory drug curcumin and the fenofibrate are combined, such that the biological safety of the preparation is improved, the lipid lowering drug fenofibrate and the anti-inflammatory drug curcumin are innovatively co-loaded, and the fenofibrate and the anti-inflammatory drug curcumin form the synergistic effect system: fenofibrate can activate peroxisome proliferator-activated receptor alpha (PPAR alpha), promote liver lipid catabolism, and reduce lipid deposition;

The application discloses an application of lactobacillus reuteri BNCC186563 in prevention and improvement of related diseases caused by high-fat diet and belongs to the technical field of microorganisms. It is found that the lactobacillus reuteri BNCC186563 can synergistically activate a PPAR alpha signal pathway and remodel a glycerophospholipid metabolism network, and the lactobacillus reuteri BNCC186563 can be used as a potential medicine, health care product and functional food for preventing and improving related diseases caused by high-fat diet, such as obesity, impaired glucose tolerance, insulin resistance, abnormal lipid metabolism, liver lipid accumulation, liver damage, inflammation and hyperlipidemia.

The present application mainly relates to a kind of composition for reducing fat and losing weight and its preparation method and application, belong to the field of biotechnology.The composition of the present application includes Cordyceps flower fruit body granules 30-60 parts, Morel fruit body granules 5-20 parts, bitter buckwheat flour 10-25 parts, mulberry leaf water extract 10-25 parts, Huangjing water extract 5-21 parts and Cassia seed water extract 1-6 parts.The above raw materials are mixed to obtain the composition of the present application.The composition of the present application can improve the blood lipid level of hyperlipidemia, inhibit the increase of body weight, reduce the volume of white adipose cells, inhibit the deposition of liver lipid, reverse the damage of liver tissue and liver function, effectively reduce fat and lose weight, and play a role in treating hyperlipidemia, obesity and fatty liver.

The invention discloses an application of ganoderic acid A in preparation of a product for preventing and / or treating a non-alcoholic fatty liver disease. The ganoderic acid A can regulate bile acid reabsorption of C57BL / 6J mice induced by high fat diet and reduce absorption of triglyceride and cholesterol. The ganoderic acid A can also enhance expression of a key enzyme cholesterol 7alpha-hydroxylase gene for liver cholesterol decomposition, so that liver cholesterol is promoted to be converted into bile acid, and accumulation of liver cholesterol is relieved. The ganoderic acid A has remarkable prevention and improvement effects on the non-alcoholic fatty liver disease induced by high fat diet by regulating bile acid metabolism, inhibiting lipid absorption and relieving liver lipid accumulation. Therefore, the ganoderic acid A can be used as a health-care product, a functional product or a medicine for preventing and treating the non-alcoholic fatty liver disease.

The application discloses a liver-protecting EPA fish oil composition for high-fat-diet people and relates to the technical field of functional health foods and dietary supplements; the application takes high-purity EPA fish oil as a core active ingredient and adopts scientific proportioning and refining processes, so that the excellent effect of EPA in regulating liver lipid metabolism is ensured, and meanwhile, the composition of the application further adds natural active ingredients which have synergistic liver-protecting effects with EPA, so that a double-path liver-protecting system is formed, liver lipid metabolism is regulated, liver cell structure is repaired, oxygen free radicals are removed, and inflammatory reactions are inhibited, and thus, comprehensive protection of the liver is realized.

The invention belongs to the technical field of biological medicine, and particularly relates to application of recombinant Glypican 1 protein in treatment of non-alcoholic steatohepatitis. The Glypican 1 protein can treat non-alcoholic steatohepatitis for the first time, experiments prove that the Glypican 1 protein can improve liver lipid deposition, inflammation, fibrosis and other key pathological characteristics, and particularly, after the serum GPC1 level is increased, the Glypican 1 protein can inhibit high-fat and high-cholesterol diet induced mouse body weight increase, optimize the ratio of liver tissue weight to body weight, and improve the non-alcoholic steatohepatitis. The glucose tolerance and the insulin sensitivity are improved, so that the metabolic disorder is integrally improved; besides, the GPC1 accelerant can directly target macrophages, inhibit expression of pro-inflammatory genes (such as Tnf and Nos2) and relieve cascade reaction of liver inflammation, the anti-inflammatory effect is achieved by inhibiting an ERK1 / 2 phosphorylation pathway in mechanism, an innovative, efficient and flexible solution is provided for NASH treatment on the whole, and the defects of current treatment means are overcome.

The invention discloses a traditional Chinese medicine composition for treating metabolism-related fatty liver diseases and application thereof, and belongs to the technical field of traditional Chinese medicines. The composition is prepared from 30 g of poria cocos, 30 g of rhizoma atractylodis macrocephalae, 30 g of radix salviae miltiorrhizae, 10 g of fructus crataegi, 15 g of pericarpium citri reticulatae, 15 g of lotus leaves, 10 g of rhizoma alismatis, 15 g of red yeast rice, 10 g of herba artemisiae scopariae and 10 g of emblic leafflower fruit according to The freeze-dried powder is prepared by adopting processes of three times of water extraction, low-temperature vacuum concentration and freeze drying, the extraction efficiency is about 37%, and active ingredients are completely reserved. Animal experiments show that the composition can significantly relieve obesity, improve liver fatty degeneration, reduce liver lipid deposition, repair liver injury, regulate dyslipidemia, improve glucose tolerance and insulin resistance, and inhibit liver lipid synthesis and inflammatory response; and no liver and kidney toxicity is caused by continuous high-dose use. The composition provided by the invention has the advantages of multiple targets, systematic regulation of metabolism, exact curative effect and high safety, and provides a novel effective traditional Chinese medicine scheme for prevention and treatment of metabolism-related fatty liver diseases.

The invention specifically discloses application of RNA binding protein FXR1 as a target spot in preparation of products for preventing and treating metabolism-related fatty liver diseases and improving glucose and lipid metabolism disorders, and relates to the technical field of biological medicines. By constructing a liver specific knockout mouse (HKO) and high-fat and high-sugar diet induction model, the invention reveals that the RNA binding protein FXR1 is a key pathogenic factor for liver fatty degeneration and metabolic disorder for the first time, and discovers that the deletion of the RNA binding protein FXR1 can significantly improve liver lipid deposition, alleviate liver injury and fibrosis, and can be used for treating liver fatty degeneration and metabolic disorder. The invention can improve the abnormal glucose tolerance and insulin resistance of the whole body, and inhibit the RNA binding protein FXR1 as a new strategy for treating liver glycolipid metabolism and metabolism-related fatty liver diseases.

Use of ganoderic acid A in the preparation of a product for preventing and / or treating non-alcoholic fatty liver disease. Ganoderic acid A can regulate bile acid reabsorption in C57BL / 6J mice induced by a high-fat diet, and reduce the absorption of triglycerides and cholesterol. Ganoderic acid A can also enhance the expression of the gene of cholesterol 7α-hydroxylase, a key enzyme for liver cholesterol decomposition, thereby promoting the conversion of liver cholesterol into bile acid, and alleviating the accumulation of liver cholesterol. Ganoderic acid A has a significant preventive and ameliorative effect on non-alcoholic fatty liver disease induced by a high-fat diet by means of regulating bile acid metabolism, inhibiting lipid absorption, and reducing liver lipid accumulation. Therefore, ganoderic acid A can be used as a health care product, a functional product, or a drug for preventing and treating non-alcoholic fatty liver disease.

The invention discloses application of a Reg4 gene in treatment of metabolism-related fatty liver, and relates to the technical field of biomedicine. The Reg4 gene is applied to the aspect of treating obesity and metabolism-related fatty liver; according to the application, by increasing expression of the Reg4 gene, liver lipid deposition, liver cell ballooning and inflammatory infiltration related to the metabolism-related fatty liver are inhibited; the application is realized by inhibiting the processes of de novo synthesis of fat in the liver, liver lipid uptake and fatty acid beta oxidation. The step of inhibiting the de novo synthesis of fat in the liver comprises the step of inhibiting the expression of genes of acetyl coenzyme A carboxylase 1, fatty acid synthase and / or stearoyl coenzyme A desaturase 1. The invention definitely proves that the Reg4 gene has an obvious effect of improving obesity and metabolism-related fatty liver, and can relieve hepatic fatty degeneration and inflammation.

The invention discloses an anti-osteosarcoma combined pharmaceutical composition and application thereof. The combined pharmaceutical composition comprises a TNF alpha inhibitor and a chemotherapeutic drug. According to the invention, the TNF alpha inhibitor and the traditional chemotherapeutic drug are combined for use for the first time to resist osteosarcoma, so that the purposes of synergistic tumor inhibition, toxicity reduction and sensitization are achieved. By intervening a neglected chemotherapy side reaction pathway of tumor-liver axis, tumor-derived extracellular vesicles are blocked to induce Kupffer cells to release TNF alpha, liver lipid droplet deposition is reduced, and expression (including Cyp1a2, Cyp2b10, Cyp3a11 and the like) of CYP metabolic enzymes is recovered, so that the metabolic capability of the liver to chemotherapy drugs is improved, and toxic and side effects are reduced. From the perspective of chemotherapy tolerance and toxic and side effect control, cardiotoxicity and myelosuppression are remarkably reduced, the overall tolerance to a chemotherapy regimen is improved, and a safer and more efficient strategy is provided.

The invention relates to a nano drug delivery system for targeted removal of liver aging cells and regulation and control of oxidative stress as well as a preparation method and application of the nano drug delivery system. The nano drug delivery system comprises cerium-doped zinc-based metal organic framework nanoparticles, a drug loaded in a hollow mesoporous structure of the nanoparticles, and a bone marrow mesenchymal stem cell membrane modified on the surfaces of the nanoparticles. According to the invention, a nano drug delivery system for breaking an'aging-inflammation 'cycle is constructed on the basis of an interaction relationship between aging cells and the non-alcoholic fatty liver disease, and the enrichment efficiency and the residence time of the nano drug delivery system at a non-alcoholic steatohepatitis disease part can be improved; the hollow mesoporous metal organic framework nano particles with the effects of efficiently removing active oxygen and being high in drug loading rate are used for loading drugs, the targeting performance on liver senescent cells, the synergistic effect and safety of removing senescent cells and adjusting the inflammatory environment are improved from the two links of drug delivery and release, and liver lipid metabolism and the inflammatory environment are improved.

The invention discloses goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder and application of the goose plasma protein source oligopeptide, and relates to the technical field of biology. The goose plasma protein source oligopeptide capable of improving liver lipid metabolism disorder is obtained through screening, and the amino acid sequence is GDWIVK. Animal experiments prove that the goose plasma protein source oligopeptide can effectively reduce the levels of triglyceride, total cholesterol and low-density lipoprotein cholesterol in serum and liver affected by high fat diet, increase the content of high-density lipoprotein cholesterol, reduce liver lipid deposition and improve pathological injury of the liver. Meanwhile, the structure and diversity of intestinal flora can be adjusted, the abundance of beneficial bacteria and the content of short-chain fatty acid in excrement are increased, the reaction of colitis is relieved, and the synergistic adjustment effect is achieved through an intestinal tract-liver axis.

The invention discloses a novel intestinal probiotic butyric acid monad and application thereof, the novel intestinal probiotic butyric acid monad is preserved in Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC No.67648. A mouse model proves that the butyric acid monad can promote synthesis of intestinal TMP (Trimethoprim) by remodeling intestinal steady state, and then the TMP is converted into thiamine. Through intestinal liver circulation, thiamine accumulates in the liver and is further converted into TPP. The process promotes the degradation of BCAs, further regulates the lipid metabolism of the liver, and obviously alleviates the progress of metabolic dysfunction related fatty liver diseases induced by high fat diet.

The present application relates to a kind of lactobacillus plantarum and its application in egg hen fatty liver, the lactobacillus plantarum (Lactobacillus plantarum) CK3 is isolated, screening is obtained from the intestinal contents of Hainan Wenchang chicken and its fecal sample, and is preserved in China typical culture preservation center on December 23, 2024, and the preservation number is CCTCC NO: M20242886, it has good tolerance in the environment of 40~55 DEG C, pH=2~4, 0.3% bile salt, 1.4% trypsin, and can reduce the liver lipid accumulation of egg hen caused by high-energy feed, liver inflammation, liver damage, reduce liver antioxidant stress, significantly improve egg hen fatty liver, while can improve the intestinal injury, intestinal inflammation and oxidative stress of fatty liver egg hen caused by high-energy feed, with important application significance and value.

The application provides application of FBXO22 in diagnosis and treatment of non-alcoholic fatty liver disease, discloses that FBXO22 is highly expressed in non-alcoholic fatty liver disease, and verifies that reducing the expression level of FEXO22 can delay the progress of non-alcoholic fatty liver disease, reduce liver inflammation and slow down liver lipid accumulation. FBXO22 can be used for diagnosis and treatment of non-alcoholic fatty liver disease, screening of candidate drugs for non-alcoholic fatty liver disease, and also can be used for efficacy evaluation, research and revelation of the pathogenesis of non-alcoholic fatty liver disease. The application has important significance for clinical research of non-alcoholic fatty liver disease.

The invention discloses application of a substance for promoting an IDH3A level in preparation of related products for treating hypercholesterolemia. According to the present invention, the IDH3A overexpression adeno-associated virus 8 (IDH3A-AAV8) is constructed for the first time, and the IDH3A-AAV8 can specifically improve the expression level of the IDH3A gene in the liver so as to effectively reduce the plasma total cholesterol level of the hypercholesterolemia model mouse, improve the liver lipid deposition and finally achieve the effective treatment of the hypercholesterolemia; meanwhile, the correlation between the IDH3A and the hypercholesteremia is disclosed for the first time, and it is proved that the hypercholesteremia can be effectively treated by improving IDH3A gene expression or enhancing IDH3A protein activity.